MedPath

Methotrimeprazine

Generic Name
Methotrimeprazine
Brand Names
Nozinan
Drug Type
Small Molecule
Chemical Formula
C19H24N2OS
CAS Number
60-99-1
Unique Ingredient Identifier
9G0LAW7ATQ

Overview

A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Indication

For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.

Associated Conditions

  • Amnesia-Memory Loss
  • Anxiety
  • Bipolar Disorder (BD)
  • Cancer Pain
  • Nausea and vomiting
  • Phantom Limb Pain (PLP)
  • Postherpetic Neuralgia
  • Schizophrenia
  • Senile psychosis
  • Trigeminal Neuralgia (TN)
  • Neurocostal neuralgia

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2015/03/02
Phase 3
Terminated

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.